ChrisMaggos

Strategic consultant seeking and implementing solutions to accelerate growth of European biotech companies.

[ChrisMaggos @ChrisMaggos]

Great feature this month in MedNous (Evernow Publishing Ltd) on the origins and potential of Kinarus Therapeutics lead product #KIN001 p38 MAPK inhibitor to treat #IPF, wet #amd, #covid19 and other #inflammation diseases. https://t.co/QXoTXQBlru

[ChrisMaggos @ChrisMaggos]

Looking forward to learning more about AC Immune's #precisionmedicine approach to developing #diagnostics and #prevention of #alzheimersdisease, #parkinsonsdisease and other #neurodegenerativediseases on April 18. https://t.co/x2RAmiMtYL

[ChrisMaggos @ChrisMaggos]

U.S. and European #biotech are always looking to #finance their development -- what are the challenges and solutions now? I'm looking forward to getting answers this Wednesday when I moderate the Demy-Colton #VirtualSalon "Fundrasing in 2023". Register h…https://t.co/neR3RUH0qV

[[iito] Life Science @iitoLifeScience]

Kinarus Therapeutics Announces Name Change and Commences Trading on SIX Swiss Exchange via Reverse Merger https://t.co/KxLwqH9zEY #KinarusTx More Swiss life science business news at [LSG] at https://t.co/EvYOliz3Ic

[ChrisMaggos @ChrisMaggos]

Insightful article by Cormac Sheridan on iOnctura's #PI3Kdelta inhibitor IOA-244’s differentiated safety, semi-allosteric mechanism, great #clinicaldata + lower #Treg in #raredisease refractory uveal #melanoma #cancer. https://t.co/HB30WaAmyl

[ChrisMaggos @ChrisMaggos]

This FT article is great exposure for our European industry and it's fantastic that there is increased awareness and excitement to invest in building centers of excellence. I hope Europe will focus less, this time, on nationalist ambitions and more on bre…https://t.co/aezqIR1azJ

[ChrisMaggos @ChrisMaggos]

Good progress today for #MSA patients, who struggle with no definitive #diagnostic test. The AC Immune alpha-synuclein PET tracers also may be developed for #parkinsonsdisease and related a-synucleinopathies. https://t.co/3cUmCZsVgI

[ChrisMaggos @ChrisMaggos]

This July I left LifeSci Advisors to embark on a new adventure in the fall.

As I reflect and prepare for my next professional challenge, it’s fulfilling to look back on the past 6 years.

It’s been a privilege to be part of building such an exceptiona…https://t.co/lPYDrnOjPQ

[ChrisMaggos @ChrisMaggos]

https://t.co/wSRAojdMQT

[ChrisMaggos @ChrisMaggos]

Collectively, the companies participating at the Nordic Biotech Conference have raised $1,429.667 million USD from the beginning of 2020 through the end of 2021Q1. Register free to join us! #biotech #funding #nordicinnovation https://t.co/qZdlOSUXS6

[ChrisMaggos @ChrisMaggos]

Looking forward to the discussion between investors and a fantastic group of companies at the Lifesci Nordic Summit! https://t.co/MxcYmzXvUa

[ChrisMaggos @ChrisMaggos]

Come chill-out after #bioeuropespring ! https://t.co/BlPf82hKbn

[ChrisMaggos @ChrisMaggos]

Looking for #talent! https://t.co/bD54kKVIWW

[ChrisMaggos @ChrisMaggos]

I'm looking forward to moderating the Rare / Orphan panel discussion this Friday at 5pm CET / 11am ET! We've invited veteran executives who have had experiences that we can all learn from. https://t.co/NliHZHfdBr

[ChrisMaggos @ChrisMaggos]

Happy Holiday from the LifeSci Advisors, LLC European team! Working closely with our U.S. and Israeli colleagues to serve our industry, the LSA Europe team has grown to over 20 staff, operating in 6 countries, and even more languages. We are grateful to…https://t.co/w4DP36T9bY

[ChrisMaggos @ChrisMaggos]

Fantastic start for an exciting new #CNS #RareDisease company - congratulations to the #founders Luigi Costa and George Garibaldi! https://t.co/kYBBbvjkwn

[ChrisMaggos @ChrisMaggos]

Fascinating read on the path of one of Europe's leading CEOs. https://t.co/bOEDDRcjuP

[ChrisMaggos @ChrisMaggos]

#pixium is bringing bionic eyes to dry #amd patients. Great 18 month data for their #prima system. https://t.co/RTfE4BhTYv

[ChrisMaggos @ChrisMaggos]

https://t.co/6SEYdmcG9y

[ChrisMaggos @ChrisMaggos]

Diaccurare published in #jci for the first time key #mechanism for #hiv resistance and #cancer immune-escape plus a promising #therapeutic candidate https://t.co/3cHJ2nzN94